rewirebio.iobenchmarks
Evidence claim

Relevance of FRASER Kremer cohort known pathogenic-event subsampling to "Select a patient-RNA splicing-variant validation workflow"

Use case
Select a patient-RNA splicing-variant validation workflow
Assessed by
FRASER Kremer cohort known pathogenic-event subsampling
Relevance
Direct evidence
Endpoint
Mean recovery of 13 known pathogenic splicing events at reduced cohort size (30 of 119 patient RNA samples) using FRASER on patient skin-fibroblast RNA

Direct patient-RNA evidence measuring recovery of known pathogenic splicing events bears on the declared decision, scoped narrowly to known-event recovery rather than diagnostic yield in unknown cases.

1 reviewed evaluation

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

15 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Citation locations
1 values
  • source id
    amp-oncology-rna-20261007-source-pmc7822922
    locator
    See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.citation_locators

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Constraints
2 values
  • Inspect every linked evaluation's source locator and preserved conflicts before citing a result.
  • Do not combine this mapping's evaluations with any other protocol's results.
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.constraints

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Endpoint
Mean recovery of 13 known pathogenic splicing events at reduced cohort size (30 of 119 patient RNA samples) using FRASER on patient skin-fibroblast RNA
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.endpoint

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Claimed field
links:assessed_by:amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.field

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Limitations
6 values
  • Direct patient-RNA known-event recovery does not establish prospective diagnostic accuracy or patient outcome benefit.
  • Known pathogenic-event ascertainment and same-cohort retrospective selection can bias recovery.
  • 30 is RNA sample subset size; do not silently equate to 30 independent patients.
  • No blinded pathogenicity adjudication, general tissue transfer, VUS reclassification sensitivity or transcriptome-wide precision established by this endpoint.
  • Subsampling repeats, exact score aggregation and numeric uncertainty unavailable from inspected main-text endpoint; supplementary PDF DNS retrieval failed.
  • FRASER author correction 2022 changes GTEx version V7 to V6p; patient-Kremer endpoint not affected according to correction search result; exact correction bytes not retrieved.
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Pinned records
6 values
  • record id
    amp-oncology-rna-20261007-issue-12-eval-fraser-2021-article-implementation
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    8963c6759c168523575320048ab0de94c29b970a518d286c460900bbf242d5df
  • record id
    amp-oncology-rna-20261007-issue-12-result-fraser-2021-article-implementation-mean-known-pathogenic-splicing-event-recovery-at-30-samples
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    83f4893f9f5db344c117dc78f108dbad3f029ed3927810a596a0f79196ef482f
  • record id
    amp-oncology-rna-20261007-issue-12-result-fraser-2021-article-implementation-mean-recovered-known-pathogenic-events-at-30-samples
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    8c7f2485c97609edc56e1f0664b675079213a745afe99b5bf3fd98c78c04678e
  • record id
    amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling
    fields
    • status
    • name
    • description
    • facets
    • source_ids
    • links
    • attributes
    sha256
    366c7dc5c429175eb4f89e57c2e8189e063366498e4d4d4f57b6ccd8d959a5ea
  • record id
    amp-oncology-rna-20261007-source-pmc7822922
    fields
    • status
    • attributes.artifact_sha256
    sha256
    bd7e82c3608d41aa8da0e2a6c2053e5ba1f5cae0a4ed9b0e3dbd853e2965d8cc
  • record id
    use-case-patient-rna-splicing-validation
    fields
    • status
    • name
    • description
    • facets
    • attributes.question
    • attributes.decision
    • attributes.inputs
    • attributes.output
    • attributes.exclusions
    • attributes.setting
    • attributes.clinical_scope
    • attributes.intended_users
    sha256
    b85cad56e15fbfad66a2e70c3b193ed56c464e5e44b62a19b12f391e409ec897
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.pins

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Rationale
Direct patient-RNA evidence measuring recovery of known pathogenic splicing events bears on the declared decision, scoped narrowly to known-event recovery rather than diagnostic yield in unknown cases.
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.rationale

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Reason
Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365).
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.reason

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Relevance
direct
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.relevance

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Revision
1
Context-only references
Detection of aberrant splicing events in RNA-seq data using FRASER

Original source ↗

amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Europe PMC fullTextXML retrieved 2026-10-07T12:23:57.289375+00:00
Retrieved: 2026-10-07T12:23:57.289375+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.revision

Source artifact SHA-256: 1f1f028cddd9145bd342422ec768ecdca6ecfeb6f9bc2e114ecfab061b5e93a6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and extraction receipts

Stable ID: use-case-mapping-amp-20261007-issue12-fraser-kremer

field
links:assessed_by:amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling
value
amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling
relevance
direct
endpoint
Mean recovery of 13 known pathogenic splicing events at reduced cohort size (30 of 119 patient RNA samples) using FRASER on patient skin-fibroblast RNA
rationale
Direct patient-RNA evidence measuring recovery of known pathogenic splicing events bears on the declared decision, scoped narrowly to known-event recovery rather than diagnostic yield in unknown cases.
constraints
Inspect every linked evaluation's source locator and preserved conflicts before citing a result.; Do not combine this mapping's evaluations with any other protocol's results.
limitations
Direct patient-RNA known-event recovery does not establish prospective diagnostic accuracy or patient outcome benefit.; Known pathogenic-event ascertainment and same-cohort retrospective selection can bias recovery.; 30 is RNA sample subset size; do not silently equate to 30 independent patients.; No blinded pathogenicity adjudication, general tissue transfer, VUS reclassification sensitivity or transcriptome-wide precision established by this endpoint.; Subsampling repeats, exact score aggregation and numeric uncertainty unavailable from inspected main-text endpoint; supplementary PDF DNS retrieval failed.; FRASER author correction 2022 changes GTEx version V7 to V6p; patient-Kremer endpoint not affected according to correction search result; exact correction bytes not retrieved.
revision
1
reason
Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365).
citation locators
source id: amp-oncology-rna-20261007-source-pmc7822922; locator: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
source locator
amp-oncology-rna-20261007-source-pmc7822922: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
review
method: automated-source-review; reviewer: codex; claude-sonnet; reviewer note: Claude Sonnet AMP-integration worker, bounded transcription of Codex-checked primary values; independently reviewed by Codex (workbench/amp-supervision/primary-review.md, integration-review-corrections.md); reviewed at: 2026-10-07T13:38:59Z; note: Bounded primary-source transcription, independently Codex-checked. No new model execution, independent experimental reproduction, qualified human scientific review or clinical validation.
reviewed evaluations
amp-oncology-rna-20261007-issue-12-eval-fraser-2021-article-implementation
pins
record id: amp-oncology-rna-20261007-issue-12-eval-fraser-2021-article-implementation; fields: status; links; attributes.origin; attributes.comparison; sha256: 8963c6759c168523575320048ab0de94c29b970a518d286c460900bbf242d5df; record id: amp-oncology-rna-20261007-issue-12-result-fraser-2021-article-implementation-mean-known-pathogenic-splicing-event-recovery-at-30-samples; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 83f4893f9f5db344c117dc78f108dbad3f029ed3927810a596a0f79196ef482f; record id: amp-oncology-rna-20261007-issue-12-result-fraser-2021-article-implementation-mean-recovered-known-pathogenic-events-at-30-samples; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 8c7f2485c97609edc56e1f0664b675079213a745afe99b5bf3fd98c78c04678e; record id: amp-oncology-rna-20261007-protocol-fraser-kremer-subsampling; fields: status; name; description; facets; source_ids; links; attributes; sha256: 366c7dc5c429175eb4f89e57c2e8189e063366498e4d4d4f57b6ccd8d959a5ea; record id: amp-oncology-rna-20261007-source-pmc7822922; fields: status; attributes.artifact_sha256; sha256: bd7e82c3608d41aa8da0e2a6c2053e5ba1f5cae0a4ed9b0e3dbd853e2965d8cc; record id: use-case-patient-rna-splicing-validation; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: b85cad56e15fbfad66a2e70c3b193ed56c464e5e44b62a19b12f391e409ec897
Related records

Suggest a correction